Judi Rx™

Medication Pipeline Report 2026 I Q2

TABLE OF CONTENTS

GLOSSARY:

PO ..... Oral

IV ..... Intravenous

SC ..... Subcutaneous

IM ..... Intramuscular

INH ..... Inhaled

INJ ..... Injectable

TD ..... Transdermal

ID ..... Intradermal

IVT ..... Intravitreal

TOP ..... Topical

OPHT ..... Ophthalmic

IN ..... Intranasal

IA ..... Intra-arterial

IT ..... Intrathecal

OT ..... Otic

CVC ..... Catheter Lock Solution

ICI ..... Intracameral implant

INTRODUCTION

Welcome to the *Judi Rx Pipeline Report*. This quarterly publication is developed by our Clinical Pharmacists and is prepared using a wide range of clinical resources. The Judi Rx Pipeline Report is designed to keep you up to date on the latest drug approvals and well-versed on what is to come in the FDA drug pipeline. Our pipeline report is one of the many ways we, at Judi Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Judi Rx is a next generation pharmacy benefits manager, overseeing prescription benefit plans on behalf of employers, unions, and government entities. Determined to transform an outdated model, Judi Rx's mission is to change the way prescription benefits are priced and administered in the US, unlocking enduring social change. Through our platform approach, Judi Rx delivers data-driven insights and actionable strategies that reduce costs, while improving patient outcomes. Our commitment to innovation, technology and service is the reason why Judi Rx is among the fastest-growing PBMs in the country.

Privacy Statement:
Judi Rx, Inc., on behalf of itself and its subsidiaries (including but not limited to Judi Health, LLC and Amino, LLC) ("we," "our," or "us") is committed to ensuring that your privacy is protected. This privacy policy describes the types of information we may collect from you or that you may provide to us and our practices for collecting, using, maintaining, protecting, and disclosing that information. This policy applies to information collected or provided through any services offered on or through judihealth.com such as the member web portal, our care navigation platform, and our mobile application accessible at the Google Play Store and iOS App Store under the name Judi Rx | Judi Health (collectively, our "Site").

The drug pipeline is subject to change.
Information in this report is current as of:
06/18/2026

LYNAVOY® (LINERIXIBAT) PO, GSK

Approval Date	03/17/2026
Indication	Treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adults
Clinical Overview	PBC is a liver autoimmune disease that causes scarring and inflammation of the small bile ducts which leads to bile and toxins building up. PBC typically occurs in women 45-65 years old and about 131,000 people in the US have this disease. Patients often experience pruritus (itching) due to PBC with about 25-53% of patients having significant pruritus. This disease is progressive in nature and if patients aren't treated, they can develop liver failure, end-stage liver disease, require a liver transplant, or it can lead to death.
Considerations	• 1st in class therapy specifically approved for treatment of cholestatic pruritus • Lynavoy® is not a disease-modifying therapy as it only treats symptoms of itching
Select Alt Therapies	Livdelzi®(seladelpar) PO, and off-label generic medications like bile acid resins, naltrexone, sertraline, and rifampin.

AVLAYAH™ (TIVIDENOFUSP ALFA-EKNM) IV, DENALI THERAPEUTICS

Approval Date	03/24/2026
Indication	Treatment of Hunter syndrome also known as Mucopolysaccharidosis II (MPS II)
Clinical Overview	MPS II is an X-linked lysosomal storage disorder that is rare and is caused by iduronate-2-sulfatase (IDS) deficiency. Low or absent IDS can lead to progressive damage across multiple organs and tissues as well as cellular dysfunction. Symptoms can start in earlier childhood between 4-8 years old with symptoms consisting of progressive cognitive decline, airway disease, joint stiffness, hepatomegaly, and cardiac death. Those with severe disease only live to the first or second decade of life while those with less severe disease can live to the fifth or sixth decade. MPS II affects about 1 in 100,000 to 170,000 male births.
Considerations	• Granted Fast Track, Priority Review, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations • Approved via FDA accelerated pathway • Healthcare administered • 1st therapy designed to cross the blood-brain barrier for this condition
Select Alt Therapies	The only current therapy in the market is Elaprase® (idursulfase) IV with additional management including cardiac, orthopedic, respiratory, neurologic, and supportive care.

LIFYORLI™(RELACORILANT) PO, CORCEPT THERAPEUTICS

Approval Date	03/25/2026
Indication	In combination with Abraxane (albumin-bound paclitaxel; nab-paclitaxel) for treatment of adults with platinum resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens (at least one which included bevacizumab)
Clinical Overview	Ovarian cancer is a broad term that includes cancers that come from the ovaries, fallopian tube, or peritoneum and are typically grouped together due to similar approaches to treatment. Within the US each year, about 21,000 women are diagnosed with ovarian cancer and 13,000 die from the disease. Treatments consist of surgery and platinum-based chemotherapy. However, platinum resistant ovarian cancer (PROC) is common and is defined as disease reoccurrence within 6 months of completing platinum-based chemotherapy. Up to 80% of patients experience recurrence and may develop increasing resistance of platinum over time. In those with PROC, the median survival is about 9-12 months, and there is currently no established standard of care for this condition.
Considerations	• WAC is $37,900 per 28 days • Does not require biomarker selection unlike Keytruda® and Elahere® therapies • Severe warnings include neutropenia, severe infections, adrenal insufficiency, and exacerbation of conditions treated with glucocorticoids
Select Alt Therapies	Keytruda® (pembrolizumab) IV and Elahere® (mirvetuximab soravtansine-gynx) IV.

KRESLADI™ (MARNETEGRAGENE AUTOTEMCEL; MARNE-CELL) IV, ROCKET PHARMA

Approval Date	03/26/2026
Indication	Severe leukocyte adhesion deficiency type I (LAD-I) in pediatrics due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant
Clinical Overview	LAD-I is a life-threatening autosomal recessive primary immunodeficiency disease of both B and T cells. It is ultra-rare as it occurs in about 1 per 1 million people. LAD-I is caused by absence or a decrease in the CD18 integrin on white blood cells due to mutations in the ITGB2 gene. This makes it so white blood cells cannot enter infection sites preventing them from fighting infections. Symptoms can include life-threatening bacterial infections of the skin, mouth, and respiratory tract. In newborns, other symptoms can include umbilical cord complications, persistent leukocytosis, and impaired wound healing. Patients with LAD-I have severe mortality risk and about 60% of patients who do not receive hematopoietic stem cell transplant (HSCT) can die from an infection within the first 2 years of life.
Considerations	• Gene therapy, one-time single dose • IPD estimates $3,000,000–$3,500,000 wholesale acquisition cost (WAC) per single dose • Granted FDA accelerated approval
Select Alt Therapies	Hematopoietic stem cell transplant (HSCT) was the only therapy used prior to the approval of Kresladi™.

PONLIMSI™ (DENOSUMAB-ADET) SC, TEVA

Approval Date	03/27/2026
Indication	Increasing bone mass, osteoporosis, and glucocorticoid-induced osteoporosis
Clinical Overview	Osteoporosis is caused by excessive reabsorption of bone which causes bones to weaken and become prone to fractures. It is the most common bone disease that affects more women than men. About 1 in every 3 women and 1 in every 5 men over the age of 50 develop osteoporosis. Risk factors for osteoporosis include age, female gender, previous fractures, menopause, family history, smoking, alcohol, poor nutrition, and vitamin D deficiency. Both prostate and breast cancer are frequent causes of bone metastases. Breast cancer causes an increase in osteoclast activity while prostate cancer causes an increase in osteoblast activity. Though prostate cancer causes new bone to form, it is spongy instead of compact and leads to a decrease in bone strength and function.
Considerations	• Biosimilar to Prolia® • Healthcare administered
Select Alt Therapies	Prolia® (denosumab) SC, Conexxence® (denosumab-bnht) SC, Jubbonti® (denosumab-bbdz) SC, Stoboclo® (denosumab-bmwo) SC, and Ospomyv™ (denosumab-dssb) SC.

OTARMENI® (LUNSOTOGENE PARVEC-CWHA) INTRACOCHLEAR, REGENERON

Approval Date	04/23/2026
Indication	Severe to profound otoferlin (OTOF)-related hearing loss
Clinical Overview	OTOF hearing loss is an ultra-rare disorder that affects about 50 newborns per year in the U.S. This disorder is caused by mutations in the OTOF gene, the protein responsible for communication between the inner ear and the auditory nerve. This protein becomes nonfunctional in this disorder and can lead to permanent congenital hearing loss. About 1.7 out of every 1,000 children in the US have permanent congenital hearing loss.
Considerations	• Gene therapy • Orphan drug, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy designations • Healthcare administered • Regeneron will provide Otarmeni® at no cost to clinically eligible U.S. individuals (does not include administration fee)
Select Alt Therapies	Prior to the approval of Otarmeni®, no medications were approved for treatment of OTOF hearing loss; only cochlear implants or hearing aids were used for treatment.

VEPPANU™ (VEPDEGESTRANT) PO, ARVINAS, PFIZER

Approval Date	05/01/2026
Indication	Estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer with an ESR1 mutation after trying at least one prior endocrine therapy
Clinical Overview	The most common cancer diagnosis in women within the US is breast cancer with ER+/HER2- accounting for about 70% of cases. Some symptoms of breast cancer may include new lumps in the breast or underarm, swelling of part of the breast, redness or flaky skin in the nipple area, nipple discharge, and any change in size or shape of the breast. Roughly 6-10% of breast cancers are metastatic (spreading to other parts of the body) at diagnosis. About 40-50% of patients with ER+/HER2-mBC develop ESR1 mutations usually after or during treatment with an aromatase inhibitor.
Considerations	• 1st proteolysis-targeting chimera therapy approved for cancer treatment • QTc prolongation warning requires monitoring at baseline and 4 weeks after starting therapy • Patients at a reproductive age should use contraception with this medication as it can cause embryo-fetal toxicity • Dosing changes should occur if Veppanu™ is used with strong CY3A4 inhibitors and inducers
Select Alt Therapies	Orserdu® (elacestrant) PO, Inluriyo™ (imlunestrant) PO.

BEQALZI™(SONROTOCLAX) PO, BEIGENE, BEONE MEDICINES

Approval Date	05/13/2026
Indication	Treatment of adults with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy (including a Bruton's tyrosine kinase inhibitor)
Clinical Overview	Non-Hodgkin's lymphoma (NHL) is a group of cancers that affect the lymphatic system. MCL is a rare type of NHL that develops from cancerous B-lymphocytes within the mantle zone region of the lymph node. MCL occurs at a rate of about 0.5-1 per 100,000 people yearly and mostly affects men between the ages of 60-70 years old (male to female ratio 4:1).Treatment management for R/R MCL is complex, however, targeted therapies and cellular therapies are becoming available for treatment.
Considerations	• FDA accelerated approval • 1st in class therapy • The starting dose begins with a 4 week ramp up phase due to the warning of tumor lysis syndrome
Select Alt Therapies	Jaypirca®(pirtobrutinib) PO, Breyanzi® (lisocabtagene maraleucel) IV, Calquence® (acalabrutinib) PO, Brukinsa® (zanubrutinib) PO, and Tecartus® (brexucabtagene autoleucel) IV.

IMMGOLIS™ (GOLIMUMAB-SLDI) SC, ARVINAS

Approval Date	05/15/2026
Indication	Moderate to severe rheumatoid arthritis (RA) in combination with methotrexate and moderate to severe ulcerative colitis (UC)
Clinical Overview	RA is a chronic inflammatory autoimmune disease that is caused by the immune system attacking healthy cells in the body, leading to inflammation in those areas. RA usually attacks the joints of the body and can attack many joints at once. Symptoms of RA may include morning stiffness, pain in shoulder, loss of mobility, neck and pelvic girdle, and development of rheumatoid nodules. RA occurs in about 0.5-1% of the US population. UC is a type of inflammatory bowel disease that occurs in the colon and rectum. It is not known exactly what causes UC. UC occurs in about 9-20 cases over 100,000 per year and is the most common type of inflammatory bowel disease. Symptoms of UC may include bloody diarrhea, stomach pain, weight loss, fever, and malaise.
Considerations	• 1st approved interchangeable biosimilar to Simponi®
Select Alt Therapies	Simponi Aria® (golimumab) IV, Simponi® (golimumab) SC, Humira® (adamlimumab) SC, Stelara® (ustekinumab) SC, Remicade® (infliximab) IV, and biosimilars available of the reference products listed.

IMMGOLIS INTRI™ (GOLIMUMAB-SLDI) IV, ARVINAS

Approval Date	05/15/2026
Indication	Moderate to severe rheumatoid arthritis (RA) in combination with methotrexate
Clinical Overview	RA is a chronic inflammatory autoimmune disease that is caused by the immune system attacking healthy cells in the body, leading to inflammation in those areas. RA usually attacks the joints of the body and can attack many joints at once. Symptoms of RA may include morning stiffness, pain in shoulder, loss of mobility, neck and pelvic girdle, and development of rheumatoid nodules. RA occurs in about 0.5-1% of the US population.
Considerations	• 1st approved interchangeable biosimilar to Simponi Aria®
Select Alt Therapies	Simponi Aria® (golimumab) IV, Simponi® (golimumab) SC, Humira® (adamlimumab) SC, Stelara® (ustekinumab) SC, Remicade® (infliximab) IV, and biosimilars available of the reference products listed.

HEPCLUDEX® (BULEVIRTIDE-GMOD) SC, GILEAD, MYR PHARMACEUTICALS

Approval Date	05/22/2026
Indication	Chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis
Clinical Overview	HDV infection is a chronic and life-threatening condition that can cause fast development of liver scarring (fibrosis), liver failure, liver cancer, and possibly lead to death. This infection only occurs in patients who have hepatitis B virus (HBV) infection. Risk factors for infection of HDV include injecting drugs, occupational exposure to blood, and unprotected sex. Vaccination for HBV does protect against both HBV and HDV. Worldwide, about 12 million people have HDV infection with prevalence in the US being around 4.6%.
Considerations	• 1st FDA approved treatment for chronic HDV • Granted Breakthrough Therapy, Priority Review, Orphan Drug, and Accelerated Approval pathway designations by the FDA • Boxed warning that discounting Hepcludex® may result in severe acute exacerbations of HDV and HBV infection
Select Alt Therapies	Before approval of Hepcludex®, there was no FDA approved medications specifically for HDV infection, however, Pegasys® (peginterferon alfa-2a) SC was used off-label.

DECNUPAZ™ (PIVEKIMAB SUNIRINE-PVZY) IV, ABBVIE

Approval Date	05/27/2026
Indication	Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult patients
Clinical Overview	BPDCN is an ultra-rare and aggressive hematology cancer. This cancer can involve bone marrow involvement, cutaneous lesions, and leukemic dissemination with skin lesions being the most prominent symptom. BPDCN occurs in about 0.7% of primary cutaneous skin cancers and mostly occurs in older adults with the average age being 65-67 years old. Prognosis is usually poor as it is an aggressive cancer that can cause death fast if not treated early with a median survival rate of 12-27 months.
Considerations	• 1st and only antibody-drug conjugate approved for this indication • More convenient dosing than Elzonris® • Dosed once every 3 weeks
Select Alt Therapies	Elzonris® (tagraxofusp-erzs) IV.

RANLUSPEC® (RANIBIZUMAB-HKDZ) IVT, LUPIN

Approval Date	06/02/2026
Indication	Wet age-related macular degeneration, diabetic retinopathy (DR), diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization (mCNV)
Clinical Overview	Wet age-related macular degeneration is a condition of the eye that causes blurred vision or decreases central vision. Symptoms usually worsen quickly and may include difficulty adjusting to low light levels, a need for brighter lights when reading, visual distortions, and difficulty recognizing faces. This disease is most common in those ≥50 years old and is 20% of all age-related macular degeneration. DR and diabetic macular edema are caused from damage overtime to the structures of the retina. DR and macular edema are major complications of diabetes with about 75% of people with type I diabetes developing DR and 25% of those with diabetes developing macular edema. Blockage to a vein that carries blood away from the retina can lead to a retinal vein occlusion. RVOs can cause swelling of the macula leading to blurry vision and even vision loss.
Considerations	• 1st biosimilar of Lucentis®
Select Alt Therapies	Lucentis® (ranibizumab) IVT, Eydenzelt® (aflibercept-boav) IVT, Pavblu™ (aflibercept-ayyh) IVT, Yesafili® (aflibercept-jbvf) IVT, Opuviz™ (aflibercept-yszy) IVT, Eylea® (aflibercept) IVT, Enzeevu™ (aflibercept-abzv) IVT, and Ahzantive® (aflibercept-mrbb) IVT.

ICOTYDE™ (ICOTROKINRA) PO, JOHNSON & JOHNSON

Approval Date	03/17/2026
Indication	Treatment of moderate to severe plaque psoriasis (PsO) in patients ≥12 years old who weigh ≥40 kg and who are candidates for systemic therapy or phototherapy
Clinical Overview	PsO is a chronic inflammatory disease that affects the skin. PsO causes abnormal keratinocyte proliferation that results in thick, raised plaques on the skin. The skin can appear red or pink with silvery white scales in some patients while others the plaques may appear purple, grey, or discolored. Plagues can cause symptoms of itchiness, burning, or stinging and usually occur on the scalp, trunk, or around the joints. Patients with PsO also have increased risk of developing other chronic conditions like inflammatory bowel disease, depression, and cardiovascular disease. In the US, PsO occurs in about 3% of adults.
Considerations	• 1st FDA approved oral therapy that inhibits interleukin-23 • Will compete as a 1st line agent for patients with plaque psoriasis
Select Alt Therapies	Tremfya® (guselkumab) SC, Stelara® (ustekinumab) SC and its biosimilars, Sotyktu® (deucravacitinib) PO, and Otezla®/Otezla® XR (apremilast) PO.

AWIQLI® (INSULIN ICODEC-ABAE) SC, NOVO NORDISK

Approval Date	03/26/2026
Indication	Improve glycemic control in type II diabetes as an adjunct to diet and exercise
Clinical Overview	More than 40 million people in the US have diabetes with 90-95% of diabetes cases being type II diabetes. Diabetes is a chronic and progressive disorder that causes high blood sugars due to inadequate levels of insulin within the body. The 2 key features of type II diabetes are insulin resistance and beta cell dysfunction. Uncontrolled type II diabetes can lead to blood vessel damage. Long-term health complications associated with diabetes include retinopathy, nephropathy, and neuropathy.
Considerations	• 1st FDA approved once weekly basal insulin • Not approved for use in patients with type I diabetes due to higher risk of hypoglycemia than Tresiba®
Select Alt Therapies	Basal insulins like Tresiba® (insulin degludec) SC, Lantus® (insulin glargine) SC, and Levemir® (insulin determir) SC.

FOUNDAYO™ (ORFORGLIPRON CALCIUM) PO, ELI LILLY, CHUGAI

Approval Date	04/01/2026
Indication	Reduce excess body weight and maintain weight reduction long term in adults who are obese or overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
Clinical Overview	Prevalence of obesity in the US is high as according to 2023 data, 40.3% of the population is obese. Obesity is a chronic health condition that is associated with significant morbidity and mortality with a high body mass index (BMI) contributing to more than 320,000 US deaths in a study done in 2014. Patients who are either obese or overweight are at greater risk for developing other chronic conditions like cardiovascular disease, type II diabetes, obstructive sleep apnea, and some types of cancer. Medication treatment is indicated for patients who have at least a BMI≥30 kg/m^2 or those who have a BMI≥27 kg/m^2 with at least one weight related condition (e.g. high blood pressure, high cholesterol, type II diabetes).
Considerations	• 5^{th} drug and 1^{st} new molecular entity approved under the Commissioner's National Priority Voucher (CNPV) pilot program • Does not have to be taken in regard to food unlike its competitor Wegovy® • WAC is $7,896 annually but in the direct-to-consumer channel, it is priced the same as Wegovy® at $299 per month • Boxed warning for increased risk of thyroid C-cell tumors
Select Alt Therapies	Wegovy® (semaglutide) PO/SC, Zepbound® (tirzepatide) SC, Saxenda® (liraglutide) SC and its generic.

IDVYNSO™ (DORAVIRINE; ISLATRAVIR) PO, MERCK & CO

Approval Date	04/20/2026
Indication	Human immunodeficiency virus-1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of virologic treatment failure
Clinical Overview	About 1.2 million people are HIV+ worldwide with 31,800 new cases happening each year in the US. Without HIV viral loads being suppressed, patients can develop acquired immunodeficiency syndrome (AIDS). Even with treatment options improving over the years for HIV, HIV-related illnesses still account for about 8,000 deaths each year. The main goal of antiretroviral therapy in patients with HIV is to prevent HIV-associated morbidity and mortality as well as transmission to others.
Considerations	• $4,455 WAC for 30-day supply • Once daily regimen • Do not administer with drugs that are strong CYP34A enzyme inducers
Select Alt Therapies	Biktarvy® (bictegravir; emtricitabine; tenofovir alafenamide) PO, Dovato® (dolutegravir; lamivudine) PO, and Cabenuva® (cabotegravir; rilpivirine) IM.

LANGLARA™ (INSULIN-GLARGINE-ALDY) SC, LANNETT, HEC PHARM, SUNSHINE LAKE PHARMA, LANEXA BIOLOGICS

Approval Date	04/29/2026
Indication	Improve glycemic control in both type I and type II diabetes
Clinical Overview	More than 40 million people in the US have diabetes with 90-95% of diabetes cases being type II diabetes. Both type I and type II diabetes are increasing in prevalence. Type I diabetes occurs typically in the younger population and is an autoimmune disorder caused by lack of beta cell production from the pancreas. Type II diabetes is not an autoimmune disorder and usually occurs later in life. Type II diabetes is caused by the body not using insulin properly though the pancreas still produces beta cells. Symptoms of type 1 and type 2 diabetes consist of frequent urination, feeling thirsty or hungry, extreme fatigue, blurry vision, and numbness in hands and feet.
Considerations	• Biosimilar of Lantus® (insulin glargine)
Select Alt Therapies	Basaglar® (insulin glargine) SC, Tresiba® (insulin degludec) SC, Lantus® (insulin glargine) SC, and Rezvoglar™ (insulin glargine-yfgn) SC.

TRIMBOW® (BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE DIHYDRATE; GLYCOPYRRONIUM BROMIDE) INH, CHIESI

Approval Date	05/14/2026
Indication	Maintenance treatment of asthma in adults
Clinical Overview	Asthma is a chronic lung condition that can cause the airways of the lungs to be inflamed and narrowed at times. This makes it hard for patients to breathe air in and out of their lungs. Asthma is common in the US as about 1 out of 13 people have it. Asthma can be triggered worse with certain factors like pollen, exercise, viral infections, or cold air. When asthma symptoms worsen, a patient can experience an asthma exacerbation (asthma attack) and if left untreated, the asthma attack can be life-threatening.
Considerations	• Triple combination inhaler that contains a long-acting beta agonist, an anticholinergic, and an inhaled corticosteroid
Select Alt Therapies	Trelegy® Ellipta® (fluticasone furoate; umeclidinium; vilanterol) INH and Breztri® Aerosphere® (budesonide; glycopyrrolate; formoterol fumarate) INH.

BAXFENDY™ (BAXDROSTAT) PO, CINCOR PHARMA, ASTRAZENECA

Approval Date	05/18/2026
Indication	Hypertension in combination with other antihypertensives in adult patients who are not adequately controlled on other agents
Clinical Overview	Hypertension (high blood pressure) occurs when the blood pushes against the walls of the arteries. Hypertension is defined as blood pressure that is consistently ≥130/80 mmHg though normal blood pressure is <120/80 mmHg. Those with high blood pressure are more at risk of developing other cardiovascular issues like heart disease, heart attack, or stroke. There are no symptoms of high blood pressure usually, but certain causes include little physical activity, diabetes, obesity, pregnancy, family history, and/or environmental factors.
Considerations	• 1st in class aldosterone synthase inhibitor • Patients must have blood tests monitored as Baxfendy™ has warnings for causing hyperkalemia (high potassium) or hyponatremia (low sodium)
Select Alt Therapies	There are many different drug classes approved to treat hypertension like calcium channel blockers (e.g. nifedipine, amlodipine), angiotensin converting enzyme (ACE) inhibitors (e.g. lisinopril), angiotensin receptor blockers (ARBs like losartan, irbesartan), and different types of diuretics (e.g. spironolactone, furosemide, hydrochlorothiazide).

ZAYNICH® (CEFEPIME; ZIDEBACTAM) IV, WOCKHARDT

Approval Date	05/29/2026
Indication	Complicated urinary tract infection (cUTI) including pyelonephritis
Clinical Overview	cUTIs are urinary tract infections that extend beyond the bladder and can include pyelonephritis (kidney infection), an UTI that causes infection of the blood or fever, catheter-associated UTI, and/or swelling of the prostate gland. Symptoms of a cUTI can include fever, rigors, back/flank pain, chills, and blood flow instability. UTIs are the most common reasons for hospital visits and are the leading cause of gram-negative blood infections. About 3 million cUTI cases occur each year and result in more than $6 billion annually in US healthcare costs.
Considerations	• Healthcare administered • Dose adjustments recommended for adults with renal impairment (estimated glomerular filtration rate <60 mL/min) • Designed for gram-negative bacteria • Warnings including neurotoxicity, Clostridioides difficile infection, prolonged prothrombin time, and positive direct Coomb's test
Select Alt Therapies	Zaynich® will most likely be used as a 2nd- or 3rd-line option after previous gram-negative antibiotic therapies such as penicillin combinations (piperacillin-tazobactam), cephalosporins (e.g., ceftriaxone, cefepime), or fluoroquinolones (e.g., levofloxacin).

XOCOVA® (ENSITRELVIR FUMARIC ACID) PO, SHIONOGI

Approval Date	06/01/2026
Indication	Post-exposure prophylaxis (PEP) of coronavirus disease 2019 (COVID-19) in patients ≥12 years old
Clinical Overview	COVID-19 is a respiratory condition caused by the SARS-CoV-2 virus. It is very contagious and can spread quickly from person to person as it spreads through droplets and very small particles that contain the virus. Typical symptoms include respiratory issues that can feel like the cold, flu, or pneumonia. Risk factors for developing severe COVID-19 illness are old age, those who are immunosuppressed, those with certain health conditions (e.g. asthma, COPD), and those with certain disabilities. As of June 1, 2024 about 1.2 million have died from COVID-19 in the US and currently the only prevention is vaccination against the disease.
Considerations	• 1st medication treatment approved for prevention of COVID-19 disease • Warning of embryo-fetal toxicity, therefore, women of childbearing age should use birth control during treatment and 2 weeks after
Select Alt Therapies	Currently the only treatment options that exist for prevention of COVID-19 disease are the COVID-19 Vaccine, mRNA vaccinations like Comirnaty® IM, Spikevax® IM, and Novaxovid™ IM.

UTEBZI ™ (TEBIPENEM PIVOXIL HYDROBROMIDE) PO, GSK, MEJI SEIKA, SPERO THERAPEUTICS

Approval Date	06/17/2026
Indication	Treatment of complicated urinary tract infections (cUTI) including pyelonephritis
Clinical Overview	cUTI are urinary tract infections that extend beyond the bladder and can include pyelonephritis (kidney infection), an UTI that causes infection of the blood or fever, catheter-associated UTI, and/or swelling of the prostate gland. Symptoms of a cUTI can include fever, rigors, back/flank pain, chills, and blood flow instability. UTIs are the most common reasons for hospital visits and are the leading cause of gram-negative blood infections. About 3 million cUTI cases occur each year and result in more than $6 billion annually in US healthcare costs.
Considerations	• 1st and only oral carbapenem antibiotic approved in the US
Select Alt Therapies	Utebzi™ will most likely be used for resistant bacteria in the outpatient setting but will compete with current broad-spectrum oral antibiotics, such as fluoroquinolones (e.g., levofloxacin), beta-lactams (e.g., amoxicillin/clavulanate), or sulfonamides (e.g., trimethoprim-sulfamethoxazole).

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Arexvy® respiratory syncytial virus	GSK	IM	Respiratory syncytial virus (RSV)	03/12/2026
Cosentyx SC® secukinumab	Novartis	SC	Hidradenitis suppurativa in pediatric patients ≥12 years old	03/12/2026
Flavalta™ lidocaine hydrochloride; epinephrine	Deproco	INJ	Local anesthesia	03/19/2026
Wegovy HD® semaglutide	Novo Nordisk	SC	Obesity	03/19/2026
Imcivree® setmelanotide acetate	Ipsen; Rhythm Pharmaceuticals	SC	Hypothalamic obesity (HO) in adults and pediatrics ≥4 years old	03/19/2026
Opdivo® nivolumab	Bristol-Myers Squibb	IV	Hodgkin's lymphoma	03/20/2026
Neffy® epinephrine	ARS Pharma	IN	Anaphylactic reactions in patients of any age if patient weighs ≥15 kg	03/26/2026
Alyftrek® deutivacaftor; tezacaftor; vanzacaftor calcium	Vertex	PO	Cystic fibrosis in patients ≥6 years old with CFTR gene mutations	03/27/2026
Trikafta® elexacaftor; ivacaftor; tezacaftor	Vertex	PO (tablets and granules)	Cystic fibrosis in patients ≥2 years old with CFTR gene mutations	03/27/2026
Zynz® retifanlimab-dlwr	Incyte; MacroGenics	IV	Anal cancer	03/30/2026

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Eylea HD® aflibercept	Regeneron	IVT	Expanded dosing interval (5 months) for wet age-related macular degeneration; diabetic macular edema	04/02/2026
Filspari® sparsentan	Ligand Pharmaceuticals	PO	Granted full approval to reduce proteinuria in patients ≥8 years old with focal segmental glomerulosclerosis	04/13/2026
Stelara SC® ustekinumab	Johnson & Johnson	SC	Crohn's disease in patients ≥6 years old	04/16/2026
Cosentyx SC® secukinumab	Novartis	SC	Ankylosing spondylitis	04/17/2026
Tzield® teplizumab-mzwv	Sanofi; Provention Bio	IV	Delay of type I diabetes in pediatrics ≥1 year old	04/20/2026
Dupixent® dupilumab	Sanofi; Genzyme; Regeneron	SC	Chronic spontaneous urticaria (CSU) in pediatrics 2-11 years old	04/22/2026
Saphnelo SC® anifrolumab	AstraZeneca; MedImmune	New dosage form: SC – self autoinjector	Systemic lupus erythematosus (SLE)	04/24/2026
Breztri Aerosphere HFA® budesonide; formoterol fumarate; glycopyrrolate	AstraZeneca; Pearl Therapeutics	INH	Maintenance treatment of asthma in patients ≥12 years old	04/27/2026

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Insulin Glargine Sunshine Lake™ insulin glargine	Lannett; HEC Pharm; Sunshine Lake Pharma; Lanexa Biologics	SC	Improve glycemic control in type I and type II diabetes	04/29/2026
Auvelity® bupropion hydrochloride; dextromethorphan hydrobromide	Axsome	PO	Agitation in Alzheimer's disease	04/30/2026
Asceniv™ immune globulin human	ADMA Biologics	IV	Primary immunodeficiency in pediatrics ≥2 years old	04/30/2026
Evdi™ trabectedin	Apotex	New generic version: INJ	Leiomyosarcoma; liposarcoma	05/01/2026
Jakafi XR™ ruxolitinib phosphate	Incyte	New extended-release version: PO	Graft versus host disease; myelofibrosis	05/01/2026
Bizengri® zenocutuzumab	Genmab; Partner Therapeutics; Merus	IV	Advanced, unresectable or metastatic cholangiocarcinoma	05/08/2026
Vyvgart® efgartigimod alfa	Argenx	IV	Generalized myasthenia gravis (gMG) regardless of antibody status	05/08/2026
Ocrevus® ocrelizumab	Roche; Genetech	IV	Relapsing-remitting multiple sclerosis (RRMS) in pediatrics ≥10 years old who weigh ≥25 kg	05/08/2026
Zerbaxa® ceftolozane tazobactam	Merck & Co; Cubist Pharmaceuticals	IV	Complicated intra-abdominal infections	05/12/2026
Inqovi® cedazuridine; decitabine	Otsuka; Astex Pharmaceuticals; Taiho	PO	Chronic myelomonocytic leukemia	05/13/2026

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Fasenra® benralizumab	AstraZeneca; MedImmune; Kyowa Kirin	SC	Hypereosinophilic syndrome	05/13/2026
Enhertu® fam-trastuzumab deruxtecan-nxki	AstraZeneca; Daiichi; Sankyo	IV	Pre-operative treatment in patients with stage II or III HER2 positive breast cancer; post operative treatment in patients who have residual invasive disease	05/15/2026
Tecentriq® atezolizumab	Roche; Genentech	IV	Muscle-invasive bladder cancer (MIBC) who have ctDNA-positive, molecular residual disease after surgery	05/15/2026
Tyenne IV® tocilizumab-aazg	Fresenius Kabi	IV	Coronavirus Disease 2019 (COVID-19)	05/20/2025
Linzess® linaclotide	Allergan; Ironwood Pharmaceuticals	PO	Chronic idiopathic constipation in pediatrics ≥2 years old	05/21/2026
Datroway® datopotamab deruxtecan-dlnk	AstraZeneca; Daiichi Sankyo	IV	Unresectable or metastatic triple-negative breast cancer in adults	05/22/2026
Uptravi® selexipag	Actelion; Johnson & Johnson	PO (tablet)	Pulmonary arterial hypertension in pediatrics ≥2 years old	05/23/2026
Imfinzi® durvalumab	AstraZeneca	IV	High-risk non-muscle invasive bladder cancer (NMIBC)	05/28/2026
Afrezza® insulin recombinant human	MannKind Corporation	INH	Type I and Type II diabetes in pediatrics ≥6 years old	05/29/2026
Cavhanza™ nilotinib	Cycle Pharmaceuticals	New formulation: PO disintegrating tablet	Chronic myeloid leukemia	06/02/2026

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Hympavzi® marstacimab	Pfizer	SC	Routine prophylaxis in patients with hemophilia A or B	06/05/2026
Keytruda Qlex™ berahyaluronidase alfa; pembrolizumab	Merck & Co; Alteogen	SC	Adult patients with clear cell renal cell carcinoma (ccRCC) in combination with Welireg®	06/12/2026
Keytruda® IV pembrolizumab	Merck & Co	IV	Adult patients with clear cell renal cell carcinoma (ccRCC) in combination with Welireg®	06/12/2026
Welireg® belzutifan	Merck & Co; Peloton Therapeutics	PO	Adult patients with clear cell renal cell carcinoma (ccRCC) in combination with Keytruda IV or Keytruda Qlex™	06/12/2026
Truqap® capivasertib	AstraZeneca; Astex Pharmaceuticals	PO	Prostate cancer	06/12/2026
Skyrizi® SC risankizumab	Boehringer Ingelheim; AbbVie	New SC dosing induction formulation	Plaque psoriasis	06/12/2026
Tzield® teplizumab-mzwv	Sanofi; Provention Bio	IV	Delay the decline of insulin production in pediatric patients ages 8 through 17 years who have been recently diagnosed with Stage 3 type 1 diabetes (T1D)	06/12/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
pneumococcal 21-valent conjugate vaccine	Merck & Co; Ligand Pharmaceuticals	IM	Pneumococcal disease	06/18/2026
belzutifan	Merck & Co; Peloton Therapeutics `	PO	Kidney cancer	06/19/2026
sodium oxybate	Tris Pharma	PO	Narcolepsy; idiopathic hypersomnia (IH)	06/20/2026
cytisinicline	Achieve Life Sciences	PO	Aid to smoking cessation	06/20/2026
pegadricase	Swedish Orphan Biovitrum; 3SBio Group; Selecta; Cartesian	IV	Gout	06/27/2026
gallium-68 edotreotide	Lantheus Medical Imaging; Jubiliant; Evergreen	IV	PET localization of neuroendocrine tumors	06/29/2026
roflumilast	Arcutis	TOP	Plaque psoriasis	06/29/2026
oxylanthanum carbonate	Spectrum Therapeutics; Unicycive Therapeutics	PO	Hyperphosphatemia in chronic kidney disease	06/29/2026
pegargiminase	Phoenix Polaris Group	IM	Mesothelioma	2Q 2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
gadoquatrane	Bayer	IV	For diagnostic MRI	2Q 2026
denosumab biosimilar	Alkem Labs; Ascend; Enzene	SC	Increasing bone mass; osteoporosis in men and postmenopausal women; glucocorticoid-induced osteoporosis	2Q 2026
denosumab biosimilar	Alkem Labs; Ascend; Enzene	SC	Hypercalcemia of malignancy; bone metastases; giant cell tumor of bone	2Q 2026
exagamglogene autotemcel	Vertex; CRISPR Therapeutics	IV	Sickle cell disease (SCD); beta-thalassemia	2Q 2026
trastuzumab	Tanvex	INJ	HER-2 positive breast cancer; gastric cancer	6/2026
olezarsen sodium	Jonis Pharmaceuticals; Akeca	SC	Hypertriglyceridemia	06/30/2026
veligrotug	Viridian Therapeutics	IV	Thyroid eye disease	06/30/2026
manganese chloride tetrahydrate	Ascelia	PO	For diagnostic MRI	07/03/2026
orca-t (TBD)	Orca Bio	INJ	Conditioning for allogenic hematopoietic stem cell transplantation	07/06/2026
atacicept	EMD Serono; ZymoGenetics; Vera Therapeutics	SC	IgA nephropathy	07/07/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
gedatolisib	Pfizer; Celcuity	IV	Breast cancer	07/17/2026
camrelizumab	Jiangsu Hengrui Medicine; Elevar Therapeutics	IV	Liver cancer	07/23/2026
isatuximab	Sanofi; AbbVie; ImmunoGen	SC	Multiple myeloma	07/23/2026
rivoceranib mesylate	Jiangsu Hengrui Medicine; LSK BioPharma; HLB Pharma; Elevar Therapeutics	PO	Liver cancer	07/23/2026
centanafadine	Otsuka	PO	Attention deficit hyperactivity disorder	07/24/2026
furosemide	MannKind Corporation; scPharmaeuticals	SC	Chronic kidney disease; chronic heart failure	07/26/2026
ethinyl estradiol; norelgestromin	Mylan; Viatris	TD	Pregnancy prevention	07/30/2026
florquinitau	Lantheus Medical Imaging; Cerveau; LuMind IDSC; En gima Biomedical	IV	Alzheimer's disease	08/13/2026
berahyaluronidase alfa; pembrolizumab	Merck & Co; Alteogen	SC	Bladder cancer	08/17/2026
pembrolizumab	Merck & Co	IV	Bladder cancer	08/17/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
iberdomide	Bristol-Myers Squibb; Celgene	PO	Multiple myeloma	08/17/2026
enfortumab vedotin	Pfizer; Astellas; Seattle Genetics; Seagen	IV	Bladder cancer	08/17/2026
deramiocel	Nippon Shinyaku; Capricor Therapeutics	IV	Cardiomyopathy associated with Duchenne muscular dystrophy	08/22/2026
pariglasgene brecaparvovec	Ultragenyx	IV	Von Gierke disease	08/23/2026
lecanemab	Eisai; Biogen; BioArctic	SC	Alzheimer's disease	08/24/2026
zanidatamab	Jazz Pharmaceuticals; Zymeworks	IV	Gastroesophageal junction cancer	08/25/2026
dasatinib	Xspray	PO	Acute lymphocytic leukemia; chronic myeloid leukemia	08/25/2026
bictegravir; lenacapavir	Gilead	PO	HIV-1 infection	08/27/2026
lutetium lu 177 edotreotide	ITM	IV	Gastroenteropancreatic neuroendocrine tumors	08/28/2026
ropeginterferon alfa-2b	PharmaEssentia; AOP Orphan	SC	Thrombocythemia	08/30/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
garetosmab	Regeneron	IV	Fibrodysplasia ossificans progressiva (FOP)	08/2026
relabotulinumtoxinA	Galderma; Ipsen; Q-Med	IM	Lateral canthal lines; glabellar lines	08/2026
tislelizumab	BeiGene BeOne Medicines	IV	Gastric cancer; gastroesophageal junction cancer; esophageal cancer	08/2026
nipocalimab	Momenta; Johnson & Johnson	IV	Warm antibody autoimmune hemolytic anemia	08/2026
rusfertide	Takeda; Protagonist Therapeutics	SC	Polycythemia vera	08/2026
ustekinumab	Johnson & Johnson	SC; IV	Ulcerative colitis	08/2026
potassium bicarbonate; potassium citrate	Advicenne	PO	Renal tubular acidosis	09/03/2026
floretyrosine F18	Telix	IV	For diagnostic imaging in glioma	09/11/2026
zidesamtinib	Nuvalent	PO	Non-small cell lung cancer (NSCLC)	09/18/2026
rebisufligene etisparvovec	Ultragenyx; Abeona Therapeutics	IV	Mucopolysaccharidosis type IIIa	09/19/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
levacetylleucine	IntraBio	PO	Ataxia telangiectasia	09/19/2026
sotatercept	Bristol-Myers Squibb; Merck & Co; Celgene; Acceleron	SC	Pulmonary arterial hypertension	09/21/2026
zilganersen	Ionis Pharmaceuticals	IT	Alexander disease (AxD)	09/22/2026
zilurgisertib	Incyte; Mirum Pharmaceuticals	PO	Fibrodysplasia ossificans progressive (FOP)	09/26/2026
lirafugratinib	Elevar Therapeutics; Relay Therapeutics	PO	Biliary tract cancer	09/27/2026
relutrigine	Praxis Precision Medicines	PO	Developmental and epileptic encephalopathy (DEE)	09/27/2026
tiratricol	PledPharma; Egetis Therapeutics; Rare Thyroid Therapeutics	PO	MCT8 deficiency (Allan Herndon Dudley syndrome)	09/28/2026
aminolevulinic acid; hydrochloride	Biofrontera	TOP	Basal cell carcinoma	09/28/2026
apixaban (oral dissolving film)	TAHO	PO	In patients with nonvalvular atrial fibrillation reduce risk of systemic embolism and stroke	3Q 2026
oveporexton	Takeda	PO	Narcolepsy	3Q 2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
denecimig	Novo Nordisk; Genmab	SC	Hemophilia A	3Q 2026
tavapadon	Pfizer; AbbVie; Cerevel Therapeutics	PO	Parkinson's disease	3Q 2026
brepocitinib	Pfizer; Roivant; Priovant Therapeutics	PO; TOP	Dermatomyositis	3Q 2026
bevacizumab	Outlook Therapeutics	OPHT	Wet age-related macular degeneration	3Q 2026
finereone	Bayer	PO	Diabetic nephropathy (kidney disease)	09/2026
sevabertinib	Bayer	PO	Non-small cell lung cancer (NSCLC)	09/2026
condoliase	Ferring Pharmaceuticals; Seikagaku	INJ	Lumbar disc herniation (LDH)	09/2026
apitegromab	Scholar Rock	IV	Spinal muscular atrophy	09/30/2026
mavacamten	Bristol-Myers Squibb; MyoKardia	PO	Hypertrophic cardiomyopathy	09/30/2026
lenvatinib mesylate	Eisai; Merck & Co	PO	Kidney cancer	10/04/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
belzutifan	Merck & Co; Pelton Therapeutics	PO	Kidney cancer	10/04/2026
ifinatamab deruxtecan	Merck & Co; Daiichi Sankyo; Harpoon Therapeutics	IV	Small cell lung cancer	10/10/2026
phentolamine mesylate	Ocuphire Pharma; Viatris; Opus Genetics	OPHT	Presbyopia	10/17/2026
leniolisib phosphate	Novartis; Pharming	PO	Activated pl3kdelta syndrome/p110delta-activating mutation causing senescent T-cells, lymphadenopathy and immunodeficiency	10/24/2026
bepirovirsen	GSK; Ionis Pharmaceuticals	SC	Chronic hepatitis B	10/26/2026
tildrakizumab	Sun; Merck & Co	SC	Psoriatic arthritis	10/29/2026
ranibizumab	Stada; Xbran; Valorum Biologics	IVT	Myopic choroidal neovascularization; wet age-related macular degeneration; macular edema following retinal vein occlusion	10/29/2026
doruxapapogene ralaplasmid	Inovio	IM	Recurrent respiratory papillomatosis (RRP)	10/30/2026
aflibercept (biosimilar)	Sam Chun Dan Pharm; Fresenius Kabi	IVT	Wet age-related macular degeneration; diabetic retinopathy, diabetic macular edema; macular edema following retinal vein occlusion	10/2026
hydrocortisone acetate	Cristcot	Rectal	Ulcerative colitis	10/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
ivonescimab	Summit Therapeutics; Akeso Biopharma	IV	Non-small cell lung cancer	11/14/2026
dexmedetomidine hydrochloride	BioXcel Therapeutics	PO	Acute agitation in bipolar patients and schizophrenic patients	11/14/2026
aficamten	Cytokinetics	PO	Hypertrophic cardiomyopathy	11/14/2026
adrabetadex	Vtesse; Beren; Mandos Health	Intrathecal	Niemann-Pick disease type C	11/17/2026
molgramostim	PARI; Savara; Fujifilm	INH	Pulmonary alveolar proteinosis (PAP)	11/22/2026
venglustat malate	Sanofi; Genzyme	PO	Type 3 gaucher disease	11/25/2026
ribitol	BridgeBio; ML Bio Solutions	PO	Limb-girdle muscular dystrophy (LGMD)	11/27/2026
neladalkib	Nuvalent	PO	Non-small cell lung cancer (NSCLC)	11/27/2026
saroglitazar magnesium	Zydus	PO	Primary biliary cholangitis	11/27/2026
amivantamab; hyaluronidase	Johnson & Johnson; Genmab; Halozyme Therapeutics	SC	Squamous cell carcinoma	11/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
asundexian	Bayer	PO	Secondary prevention of stroke and acute cardiac events	11/2026
povetacicept	Vertex; Alpine Immune Sciences	SC	IgA nephropathy	11/30/2026
bezuclastinib	Unum Therapeutics; Cogent Biosciences	PO	Gastrointestinal cancer	11/30/2026
giredestrant	Roche; Genentech	PO	Hormone receptor positive breast cancer	11/30/2026
zanzalintinib	Exelixis	PO	Colorectal cancer	12/03/2026
obinutuzumab	Roche; Genentech; Biogen	IV	Systemic lupus erythematosus	12/04/2026
imsidolimab	Vanda Pharmaceuticals; AnaptysBio	IV; SC	Pustular psoriasis	12/12/2026
giredestrant	Roche; Genentech	PO	Hormone receptor positive breast cancer	12/18/2026
tirabrutinib hydrochloride	Gilead; Ono Pharmaceutical	PO	Primary central nervous system lymphoma	12/18/2026
imlifidase	Hansa Biopharma	IV	Desensitization therapy in kidney transplant recipients	12/19/2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
lorundrostat	Mineralys Therapeutics	PO	Hypertension	12/22/2026
anitocabtagene autoleucel	Gilead; Kite Pharma; Arcellx	IV	Multiple myeloma	12/23/2026
meloxicam	Viatris	PO	Post-operative pain	12/27/2026
bezuclastinib	Unum Therapeutics; Cogent Biosciences	PO	Systemic mastocytosis (SM)	12/30/2026
gefurulimab	AstraZeneca; Alexion	SC	Myasthenia gravis	2H 2026
sacituzumab govitecan	Gilead; Immunomedics	IV	Breast cancer	2H 2026
remibrutinib	Novartis	PO	Chronic inducible urticaria (CIndU)	2H 2026
secukinumab	Novartis	SC	Polymyalgia rheumatica	2H 2026
lutetium lu 177 vipivotide; tetraxetan	Novartis; Endocyte	IV	Prostate cancer	2H 2026
pimicotinib hydrochloride	EMD Serono; Abbisko Therapeutics	PO	Tenosynovial giant cell tumor (TGCT)	2H 2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
somapacitan	Novo Nordisk	SC	Short stature associated with Turner syndrome	2H 2026
baricitinib	Eli Lilly; Incyte	PO (tablet and oral suspension)	Alopecia areata	2H 2026
berahyaluronidase alfa; pembrolizumab	Merck & Co; Alteogen	SC	Breast cancer	2H 2026
tirzepatide	Eli Lilly	SC	Reduce cardiovascular mortality in patients with type II diabetes	2H 2026
pembrolizumab	Merck & Co	IV	Breast cancer	2H 2026
ianalumab	Novartis; MorphoSys	IV; SC	Sjogren's syndrome	2H 2026
insulin efsitora alfa	Eli Lilly	SC	Improve glycemic control in type 2 diabetes	2H 2026
varegacestat	Bristol-Myers Squibb; Ayala Pharmaceuticals; Immunome	PO	Desmoid tumors/aggressive fibromatosis (DT/AF)	4Q 2026
upadacitinib	AbbVie	PO	Vitiligo	4Q 2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
TBD - ReNu	Organogenesis	INJ	Osteoarthritis of the knee	4Q 2026
pirtobrutinib	Eli Lilly; Loxo Oncology	PO	Chronic lymphocytic leukemia	4Q 2026
delgocitinib	LEO Pharma; Japan Tobacco	TOP	Atopic dermatitis	4Q 2026
teclistamab	Johnson & Johnson; Genmab	SC	Multiple myeloma	4Q 2026
pritelivir	AiCuris	PO	Genital herpes	4Q 2026
ozekibart	Inhibrx Biosciences	IV	Bone cancer	4Q 2026
talquetamab	Johnson & Johnson	SC	Multiple myeloma	4Q 2026
cemdisiran	Regeneron; Alnylam Pharmaceuticals	SC	Myasthenia gravis	4Q 2026
omalizumab	Amneal; Kashiv BioSciences	SC	Chronic idiopathic urticaria (CIU)	4Q 2026
bevacizumab	Henlius	IV	Glioblastoma multiforme; colorectal cancer; cervical cancer	4Q 2026

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
cabozantinib	Lotus Pharmaceuticals	PO	Medullary thyroid cancer; kidney cancer; liver cancer; differentiated thyroid cancer	4Q 2026
pertuzumab	Biocon	IV	HER2 positive breast cancer	4Q 2026
relacorilant	Corcept Therapeutics	PO	Cushing's syndrome	12/2026
abatacept	Dr. Reddy's Laboratories	IV	Psoriatic arthritis; rheumatoid arthritis; juvenile idiopathic arthritis	12/2026
golimumab	Teva; Alvogen; Alvotech	IV; SC	Rheumatoid arthritis	12/2026
aflibercept	Teva; Alvogen; Alvotech	IVT	Wet-age related macular degeneration	12/2026